MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-09-2022
Epizyme Total Shareholders Equity 2011-2025 | EPZM
Annual Total Shareholders Equity Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -20.7 M | 185 M | 331 M | 233 M | 235 M | 202 M | 170 M | 160 M | 104 M | -51.1 M | -50.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 331 M | -51.1 M | 136 M |
Quarterly Total Shareholders Equity Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -20.3 M | 11.1 M | -20.7 M | 15.4 M | 67.6 M | 123 M | 185 M | 185 M | 185 M | 185 M | 331 M | 331 M | 331 M | 331 M | 233 M | 233 M | 233 M | 233 M | 235 M | 235 M | 235 M | 235 M | 202 M | 202 M | 202 M | 202 M | 170 M | 170 M | 170 M | 170 M | 160 M | 160 M | 160 M | 160 M | 104 M | 104 M | 104 M | 104 M | -51.1 M | -51.1 M | -51.1 M | - | -50.6 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 331 M | -51.1 M | 154 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M |  USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
106 M | $ 4.75 | 1.61 % | $ 788 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
156 M | $ 3.29 | -2.08 % | $ 254 M | USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 25.32 | -2.24 % | $ 1.23 B | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
39.5 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
518 M | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
884 M | $ 209.8 | -0.17 % | $ 5 B |  Danmark |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M |  Israel |
 |
Aptorum Group Limited
APM
|
21.1 M | $ 1.31 | -1.88 % | $ 7.14 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.34 | -2.47 % | $ 8.04 B |  Australia |
 |
AstraZeneca PLC
AZN
|
15.6 B | $ 89.69 | -0.67 % | $ 96.9 B | Britain |
 |
Anika Therapeutics
ANIK
|
212 M | $ 9.55 | 0.58 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.33 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
2.02 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | USA |
 |
Benitec Biopharma
BNTC
|
97.3 M | $ 12.34 | -4.78 % | $ 508 M | USA |
 |
Aytu BioScience
AYTU
|
19 M | $ 2.35 | 3.0 % | $ 14.8 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
673 M | - | -6.81 % | $ 3.04 B | USA |
 |
Baudax Bio
BXRX
|
-24.2 M | - | 0.59 % | $ 63 K | USA |
 |
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | USA |
 |
ChromaDex Corporation
CDXC
|
46.1 M | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
2.33 B | $ 568.91 | -2.09 % | $ 43.1 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.44 M | $ 0.28 | -2.28 % | $ 609 M | Israel |
 |
Catalyst Biosciences
CBIO
|
-15.8 M | $ 14.62 | -4.54 % | $ 962 M | USA |
 |
Cerus Corporation
CERS
|
56.1 M | $ 2.19 | 1.63 % | $ 404 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-12.6 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
29.6 M | - | -16.75 % | $ 25.8 M | USA |
 |
Clovis Oncology
CLVS
|
-279 M | - | -7.23 % | $ 13 M | USA |
 |
Biogen
BIIB
|
16.7 B | $ 174.71 | 1.28 % | $ 25.4 B | USA |
 |
BioVie
BIVI
|
19 M | $ 1.46 | -3.61 % | $ 2.16 M | USA |
 |
Celldex Therapeutics
CLDX
|
747 M | $ 27.71 | -0.82 % | $ 1.78 M | USA |
 |
Cortexyme
CRTX
|
85.1 M | - | -1.05 % | $ 67.1 M | USA |
 |
Cellectar Biosciences
CLRB
|
-15.2 M | $ 3.62 | -4.86 % | $ 44.2 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
351 M | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-739 M | $ 11.45 | 0.09 % | $ 741 M | USA |
 |
BioNTech SE
BNTX
|
1.37 B | $ 94.91 | -1.14 % | $ 27.2 B |  Germany |
 |
Eloxx Pharmaceuticals
ELOX
|
-10.7 M | - | -5.68 % | $ 8.28 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Enochian Biosciences
ENOB
|
-21.3 M | - | - | $ 40.5 M | USA |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |